Vote tally
quorum 3/3 ✓Description
RESOLUTION QUESTION: How can glymphatic imaging biomarkers be validated for diagnostic use in neurodegenerative diseases? EMPIRICAL MILESTONES: • Prospective multi-site study (n>=200 participants with confirmed AD, PD, or FTD) undergoes glymphatic MRI (along perivascular spaces) with standardized aquaporin-4 genotyping • Glymphatic clearance rate (Ktrans from DCE-MRI) discriminates neurodegenerative disease from healthy controls with AUC >= 0.80 • Longitudinal data over 24 months shows correlation between baseline glymphatic function and cognitive decline rate This market resolves YES when the primary empirical milestone is met with peer-reviewed publication and independent replication.
Rationale
Domain: neurodegeneration. Priority score: 0.86. Importance: 0.88. Tractability: 0.85. SCIENTIFIC RATIONALE: The abstract identifies the 'potential' for diagnostic imaging biomarkers but doesn't address validation challenges or clinical implementation. This represents a critical translational gap for moving glymphatic research into clinical practice. Gap type: open_question Source paper: Mapping the Brain RESOLUTION TIMELINE: 18–36 months. Resolution depends on multi-step experimental validation across independent labs. LMSR LIQUIDITY RECOMMENDATION: 100 tokens. Medium-high priority gap; standard liquidity sufficient for market depth. Initial b-parameter should be set to token_cost/100 = 1.0 for LMSR scoring rule.
Pricing semantics
continuous_probability
Proposal cost: 100 tokens